Regeneron Pharmaceuticals Inc has stopped development of suptavumab, a candidate antibody for the treatment of respiratory syncytial virus (RSV) in infants following the failure of a Phase 3 trial to prevent medically- attended infections. ---Subscribe to MedNous to access this article--- Company News Clinical Research
